v3.26.3
Organization and Description of Business
9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business

Note 1 – Organization and Description of Business

 

Jupiter Neurosciences, Inc. (the “Company”) is a clinical stage research and development pharmaceutical company located in Palm Beach Gardens, Florida. The Company incorporated in Delaware in January 2016. The Company is advancing a therapeutic pipeline targeting central nervous system (“CNS”) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, the Company’s proprietary, enhanced resveratrol formulation that has demonstrated potential for significantly improved bioavailability. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with an ongoing Phase IIa clinical study in Parkinson’s disease. The Company’s Nugevia product line brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function.

 

JOTROL™ has the potential to deliver a therapeutically effective dose of resveratrol in the blood stream, using a unique patented micellar formulation, without causing gastrointestinal side effects. We expect JOTROL™, based on the results of our Phase I study, will resolve the major obstacle of resveratrol’s poor bioavailability, which has been documented in various scientific articles describing previously conducted human trials with resveratrol as well as preclinical trial results in mice and rats.

 

In July 2026, the Company obtained exclusive U.S., including its territories, possessions and commonwealths, including Puerto Rico, license rights from PharmAla Biotech Holdings Inc. (“PharmAla”) to develop, manufacture and commercialize products incorporating or derived from ALA-002, a proprietary, investigational, next-generation MDMA formulation consisting of a non-racemic mixture of MDMA enantiomers.

 

Reverse Stock Split

 

On August 6, 2026, the Company filed a Certificate of Amendment to its Certificate of Incorporation and effected a 1-for-75 reverse stock split of its common stock (the “Reverse Stock Split”), effective at 4:01 p.m. Eastern Time. Every seventy-five shares of issued and outstanding common stock were combined into one share. The par value of the common stock remained $0.0001 per share, and the authorized number of shares of common stock was not reduced. The Reverse Stock Split was effected on a holder-by-holder basis. No fractional shares were issued; fractional interests were rounded down, and holders otherwise entitled to a fractional share were entitled to receive cash in lieu thereof based on the split-adjusted closing sales price of the Company’s common stock on August 5, 2026. All share and per-share amounts for all periods presented, have been retrospectively adjusted to reflect the Reverse Stock Split. The reduction in the stated value of common stock resulting from the Reverse Stock Split was reclassified to additional paid-in capital. This presentation adjustment decreased common stock and increased additional paid-in capital by $5,702 and $3,398 as of September 30, 2026 and December 31, 2025, respectively, and had no effect on total stockholders’ equity (deficit), net loss, loss per common share or cash flows.

 

Standby Equity Purchase Agreement

 

On October 24, 2025, the Company entered into the SEPA, pursuant to which the Company has the right to sell to an investor up to $20.0 million of its common stock, par value $0.0001 per share, subject to certain limitations and conditions. See Note 5 – Standby Equity Purchase Agreement and Convertible Debt for further details.

 

Registered Direct Offering

 

On May 20, 2026, the Company entered into a Securities Purchase Agreement with the May Investors, pursuant to which the Company agreed to issue and sell 95,238 shares of common stock of the Company at a price of $21.00 per share, for aggregate gross proceeds to the Company of approximately $2.0 million. Placement agent fees were $140,000 and proceeds after offering expenses were $1,860,000.

 

On August 21, 2026, the Company entered into a Securities Purchase Agreement with the August Investors pursuant to which the Company agreed to issue and sell the August Offering to sell 307,692 shares of common stock of the Company at a price of $6.50 per share, for aggregate gross proceeds to the Company of approximately $2.0 million. Placement agent fees were $140,000 and proceeds after offering expenses were $1,860,000

 

Nasdaq Minimum Bid Price Compliance

 

On February 26, 2026, the Company received two written notices from the Listing Qualifications Department of Nasdaq notifying the Company that (i) the listing of the Company’s Common Stock was not in compliance with the minimum bid price requirement as set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing of its Common Stock on The Nasdaq Capital Market, as the closing bid price of the Common Stock was less than $1.00 per share for the previous 30 consecutive business days, and (ii) for the 30 consecutive business days ended February 26, 2026, the Company’s market value of listed securities closed below the $35 million threshold required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2).

 

 

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided 180 calendar days, or until August 25, 2026, to regain compliance by maintaining a minimum closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days. On August 27, 2026, Nasdaq notified the Company that it had regained compliance with the minimum bid price requirement after maintaining a closing bid price of at least $1.00 for ten consecutive business days from August 13 through August 26, 2026. Separately, Nasdaq notified the Company that the Staff had determined to delist its common stock because the Company had not regained compliance with the market value of listed securities requirement or an alternative requirement under Listing Rule 5550(b). The Company timely appealed the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel. The Company subsequently appeared before the Panel and presented its case in support of continued listing on The Nasdaq Capital Market.

 

On November 3, 2026, the Panel granted the Company an extension until November 16, 2026 to regain compliance. The Company will not regain compliance within the term of the extension. Accordingly, on November 16, 2026, the Company submitted a request to Nasdaq for a further extension to December 11, 2026. If Nasdaq declines to grant the Company an additional extension, its common stock will be delisted from Nasdaq.